Miriplatin

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).^[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.^[1]

Miriplatin

Clinical data
Trade names	Miripla
Legal status
Legal status	Rx in Japan
Identifiers
IUPAC name Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
CAS Number	141977-79-9
PubChem CID	9832045
ChemSpider	8007775
UNII	780F0P8N4I
KEGG	D06294
CompTox Dashboard (EPA)	DTXSID101136455
Chemical and physical data
Formula	C34H68N2O4Pt
Molar mass	764.012 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]
InChI InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1 Key:BGIHRZPJIYJKAZ-BLUNCNMSSA-L

See also

• Oxaliplatin